Participant flow

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) · Source last updated 2023-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).

   id

   FG000

   title

   Pembrolizumab

2. description

   Participants received Investigator's choice of paclitaxel 80-100 mg/m\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).

   id

   FG001

   title

   Chemotherapy

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         31

      2. group Id

         FG001

         num Subjects

         29

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         270

      2. group Id

         FG001

         num Subjects

         262

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         19

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         4

      type

      Sponsor's decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         314

      2. group Id

         FG001

         num Subjects

         314

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         314

      2. group Id

         FG001

         num Subjects

         296

      type

      Treated

   3. achievements

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         0

      type

      Received Second Course of Pembrolizumab

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         314

      2. group Id

         FG001

         num Subjects

         314

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

At the time of the primary analysis data cut-off of 15-Oct-2018, 67 participants were ongoing in the study.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice